Treatment of epilepsy with mesenchymal stem cells: literature review

Cover Page

Cite item

Full Text

Abstract

In the past few years, results from experimental and clinical studies have shown that inflammation can be both a consequence and a cause of epilepsy. Distinctive features of mesenchymal stem cells (MSCs) are their immunomodulatory and anti-inflammatory properties, which indicate promise in the field of epilepsy treatment.

The article presents a review on the preclinical and clinical use of MSCs in the treatment of epilepsy, and outlines the mechanism of MSCs therapeutic action of in this disease. The authors focused on the analysis of all available in the literature clinical cases of MSCs use in the treatment of epilepsy, as well as the effectiveness and undesirable effects of therapy. The use of MSCs indeed has a significant effect in reducing the number of seizures and has a positive effect on mental functions, however, at present, this method of therapy is not ready for widespread clinical use due to the short period of observation in clinical trials and increased risks of developing immunological and oncological complications in patients.

About the authors

R. G. Gamirova

Kazan (Volga Region) Federal University

Author for correspondence.
Email: r-gamirov@mail.ru
ORCID iD: 0000-0002-8582-592X

Rimma Gabdulbarovna Gamirova

18 Kremlyovskaya St., Kazan 420008

Russian Federation

A. A. Shaymardanova

Kazan (Volga Region) Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0001-5151-7163

18 Kremlyovskaya St., Kazan 420008

Russian Federation

A. Yu. Barkov

Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-4232-3994

23 Kropotkinskiy Pereulok, Moscow 119034

Russian Federation

A. A. Rizvanov

Kazan (Volga Region) Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-9427-5739

18 Kremlyovskaya St., Kazan 420008

Russian Federation

D. S. Chulpanova

Kazan (Volga Region) Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-3362-8967

18 Kremlyovskaya St., Kazan 420008

Russian Federation

A. I. Mullagulova

Kazan (Volga Region) Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0001-9152-2338

18 Kremlyovskaya St., Kazan 420008

Russian Federation

V. V. Solovyeva

Kazan (Volga Region) Federal University

Email: fake@neicon.ru
ORCID iD: 0000-0002-8776-3662

18 Kremlyovskaya St., Kazan 420008

Russian Federation

References

  1. Abdanipour A., Tiraihi T., Mirnajafi-Zadeh J. Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell. Neurol Res 2011;33(6):625–32. doi: 10.1179/1743132810Y.0000000018
  2. Agadi S., Shetty A.K. Concise review: prospects of bone marrow mononuclear cells and mesenchymal stem cells for treating status epilepticus and chronic epilepsy. Stem Cells 2015;33(7):2093–103. doi: 10.1002/stem.2029
  3. Berebichez-Fridman R., Montero-Olvera P.R. Sources and clinical applications of mesenchymal stem cells: state-of-the-art review. Sultan Qaboos Univ Med J 2018;18(3):e264–e277. doi: 10.18295/squmj.2018.18.03.002
  4. Corcione A., Benvenuto F., Ferretti E. et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107(1):367–72. doi: 10.1182/blood-2005-07-2657
  5. Cui L., Kerkelä E., Bakreen A. et al. The cerebral embolism evoked by intra-areterial delivery of allogenic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther 2015;6(1):11. doi: 10.1186/scrt544
  6. Cunningham J.J., Ulbright T.M., Pera M.F. et al. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 2012;30(9):849–57. doi: 10.1038/nbt.2329
  7. DaCosta J.C., Portuguez M.W., Marinowic D.R. et al. Safety and seizure control in patients with mesial temporal lobe epilepsy treated with regional superselective intra-arterial injection of autologous bone marrow mononuclear cells. J Tissue Eng Regen Med 2018;12(2):e648–e656. doi: 10.1002/term.2334
  8. Dong H., Li G., Shang C. et al. Umbilical cord mesenchymal stem cell (UC-MSCs) transplantations for cerebral palsy. Am J Transl Res 2018;10(3):901–6.
  9. Fischer U.M., Harting M.T., Jimenez F. et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009;18(5):683–92. doi: 10.1089/scd.2008.0253
  10. Fukumura S., Sasaki M., Kataoka-Sasaki Y. et al. Intravenous infusion of mesenchymal stem cells reduces epileptogenesis in a rat model of status epilepticus. Epilepsy Res 2018;141:56–63. doi: 10.1016/j.eplepsyres.2018.02.008
  11. Hlebokazov F., Dakukina T., Ihnatsenko S. et al. Treatment of refractory epilepsy patients with autologous mesenchymal stem cells reduces seizure frequency: An open label study. Adv Med Sci 2017;62(2):273–9. doi: 10.1016/j.advms.2016.12.004
  12. Hlebokazov F., Dakukina T., Potapnev M. et al. Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients. Clin Neurol Neurosurg 2021;207:106736. doi: 10.1016/j.clineuro.2021.106736
  13. Huang P.Y., Shih Y.H., Tseng Y.J. et al. Xenograft of human umbilical mesenchymal stem cells from Wharton’s jelly as a potential therapy for rat pilocarpine-induced epilepsy. Brain Behav Immun 2016;54:45–58. doi: 10.1016/j.bbi.2015.12.021
  14. Huicong K., Zheng X., Furong W. et al. The imbalanced expression of adenosine receptors in an epilepsy model corrected using targeted mesenchymal stem cell transplantation. Mol Neurobiol 2013;48(3):921–30. doi: 10.1007/s12035-013-8480-0
  15. Jiang W., Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020;53(1):e12712. doi: 10.1111/cpr.12712
  16. Le Blanc K., Rasmusson I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439–41. doi: 10.1016/S0140-6736(04)16104-7
  17. Li P., Gong Z., Shultz L.D. et al. Mesenchymal stem cells: From regeneration to cancer. Pharmacol Ther 2019;200:42–54. doi: 10.1016/j.pharmthera.2019.04.005
  18. Liu J., Liu Q., Chen X. The immunomodulatory effects of mesenchymal stem cells on regulatory B сells. Front Immunol 2020;14(11): 1843. doi: 10.3389/fimmu.2020.01843
  19. Long Q., Upadhya D., Hattiangady B. et al. Intranasal MSCs-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc Natl Acad Sci USA 2017;114(17):E3536–E3545. doi: 10.1073/pnas.1703920114
  20. Melief S.M., Schrama E., Brugman M.H. et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells 2013;31(9):1980–91. doi: 10.1002/stem.1432
  21. Milczarek O., Jarocha D., Starowicz-Filip A. et al. Multiple autologous bone marrow-derived CD271(+) mesenchymal stem cell transplantation overcomes drug-resistant epilepsy in children. Stem Cells Transl Med 2018;7(1):20–33. doi: 10.1002/sctm.17-0041
  22. Perucca P., Scheffer I.E., Kiley M. The management of epilepsy in children and adults. Med J Aust 2018;208(5):226–33. doi: 10.5694/mja17.00951
  23. Pitkänen A., Lukasiuk K., Dudek F.E. et al. Epileptogenesis. Cold Spring Harb Perspect Med 2015;5(10):a022822. doi: 10.1101/cshperspect.a022822
  24. Pittenger M.F., Discher D.E., Péault B.M. et al. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22. doi: 10.1038/s41536-019-0083-6
  25. Rana A., Musto A.E. The role of inflammation in the development of epilepsy. J Neuroinflamm 2018;15(1):144. doi: 10.1186/s12974-018-1192-7
  26. Rani S., Ryan A.E., Griffin M.D. et al. Mesenchymal stem cellderived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther 2015;23(5):812–23. doi: 10.1038/mt.2015.44
  27. Ren G., Zhang L., Zhao X. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2(2):141–50. doi: 10.1016/j.stem.2007.11.014
  28. Rodríguez-Fuentes D.E., Fernández-Garza L.E., Samia-Meza J.A. et al. Mesenchymal stem cells current clinical applications: a systematic review. Arch Med Res 2021;52(1):93–101. doi: 10.1016/j.arcmed.2020.08.006
  29. Salem N.A., El-Shamarka M., Khadrawy Y. et al. New prospects of mesenchymal stem cells for ameliorating temporal lobe epilepsy. Inflammopharmacology 2018;26(4):963–72. doi: 10.1007/s10787-018-0456-2
  30. Shaimardanova A.A, Chulpanova D.S., Mullagulova A.I. et al. Gene and cell therapy for epilepsy: a mini review. Front Mol Neurosci 2022 11;15:868531. doi: 10.3389/fnmol.2022.868531
  31. Shi C. Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 2012;136(2):133–8. doi: 10.1111/j.1365-2567.2012.03567.x
  32. Shi Y., Su J., Roberts A.I. et al. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012;33(3):136–43. doi: 10.1016/j.it.2011.11.004
  33. Shorvon S. The concept of symptomatic epilepsy and the complexities of assigning cause in epilepsy. Epilepsy Behav 2014;32:1–8. doi: 10.1016/j.yebeh.2013.12.025
  34. Sole A., Grossetête S., Heintzé M. et al. Unraveling ewing sarcoma tumorigenesis originating from patient-derived mesenchymal stem cells. Cancer Res 2021;81(19):4994–5006. doi: 10.1158/0008-5472.CAN-20-3837
  35. Szczepanik E., Mierzewska H., Antczak-Marach D. et al. Intrathecal infusion of autologous adipose-derived regenerative cells in autoimmune refractory epilepsy: evaluation of safety and efficacy. Stem Cells Int 2020;2020:7104243. doi: 10.1155/2020/7104243
  36. Tropel P., Platet N., Platel J. C. et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006;24(12):2868–76. doi: 10.1634/stemcells.2005-0636
  37. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8(9):726–36. doi: 10.1038/nri2395
  38. Venturin G. T., Greggio S., Marinowic D.R. et al. Bone marrow mononuclear cells reduce seizure frequency and improve cognitive outcome in chronic epileptic rats. Life Sci 2011;89(7–8):229–34. doi: 10.1016/j.lfs.2011.06.006
  39. Voulgari-Kokota A., Fairless R., Karamita M. et al. Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function. Exp Neurol 2012;236(1):161–70. doi: 10.1016/j.expneurol.2012.04.011
  40. Wang L., Zhao Y., Pan X. et al. Adipose-derived stem cell transplantation improves learning and memory via releasing neurotrophins in rat model of temporal lobe epilepsy. Brain Res 2021;1750:147121. doi: 10.1016/j.brainres.2020.147121
  41. Yagi H., Soto-Gutierrez A., Parekkadan B. et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19(6):667–79. doi: 10.3727/096368910X508762

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 22926 от  12.01.2006.